EU finds drug firms make billions stalling generics

EUROPEAN patients, taxpayers and national treasuries are being fleeced of billions of euros because of the big pharmaceutical companies' elaborate campaigns to delay the marketing of cheaper generic drugs, the European Commission says.

"There is something rotten in the state [of the pharmaceutical industry]," said Neelie Kroes, the Competition Commissioner, unveiling the findings of an 18-month inquiry. "Makers of original medicines are actively trying to delay the entry of generic medicines on to their markets."

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA